Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis

Yasushi Kobayashi, Kuniyuki Kawai, Hitoshi Honda, Shin Tomida, Naoya Niimi, Takuya Tamatani, Masayuki Miyasaka, Yasunobu Yoshikai

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    We obtained the evidence that coadministration in vivo of mAbs against leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) suppressed the progression of experimental allergic encephalomyelitis (EAE) in rats. The suppressive effect in vivo of coadministration of the mAbs during the induction phase was not prominent, but the administration of these mAbs during the effector phase markedly suppressed the progression of clinical illness and prevented the infiltration of encephalitogenic cells into the central nervous system. However, administration of the mAb to LFA-1 alone or ICAM-1 alone did not show such suppressive effects. These findings suggest that LFA-1 and ICAIM-1 are critically involved in the development of EAE and that the administration together of mAbs against adhesion molecules including LFA-1 and ICAM-1 might provide a new immunotherapeutic approach for the treatment of multiple sclerosis.

    Original languageEnglish
    Pages (from-to)295-305
    Number of pages11
    JournalCellular Immunology
    Volume164
    Issue number2
    DOIs
    Publication statusPublished - Sep 1995

    Fingerprint

    Lymphocyte Function-Associated Antigen-1
    Autoimmune Experimental Encephalomyelitis
    Intercellular Adhesion Molecule-1
    Antibodies
    Multiple Sclerosis
    Central Nervous System

    All Science Journal Classification (ASJC) codes

    • Immunology

    Cite this

    Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. / Kobayashi, Yasushi; Kawai, Kuniyuki; Honda, Hitoshi; Tomida, Shin; Niimi, Naoya; Tamatani, Takuya; Miyasaka, Masayuki; Yoshikai, Yasunobu.

    In: Cellular Immunology, Vol. 164, No. 2, 09.1995, p. 295-305.

    Research output: Contribution to journalArticle

    Kobayashi, Yasushi ; Kawai, Kuniyuki ; Honda, Hitoshi ; Tomida, Shin ; Niimi, Naoya ; Tamatani, Takuya ; Miyasaka, Masayuki ; Yoshikai, Yasunobu. / Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. In: Cellular Immunology. 1995 ; Vol. 164, No. 2. pp. 295-305.
    @article{4fe10355f5d64208a5e4f0dc908b1148,
    title = "Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis",
    abstract = "We obtained the evidence that coadministration in vivo of mAbs against leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) suppressed the progression of experimental allergic encephalomyelitis (EAE) in rats. The suppressive effect in vivo of coadministration of the mAbs during the induction phase was not prominent, but the administration of these mAbs during the effector phase markedly suppressed the progression of clinical illness and prevented the infiltration of encephalitogenic cells into the central nervous system. However, administration of the mAb to LFA-1 alone or ICAM-1 alone did not show such suppressive effects. These findings suggest that LFA-1 and ICAIM-1 are critically involved in the development of EAE and that the administration together of mAbs against adhesion molecules including LFA-1 and ICAM-1 might provide a new immunotherapeutic approach for the treatment of multiple sclerosis.",
    author = "Yasushi Kobayashi and Kuniyuki Kawai and Hitoshi Honda and Shin Tomida and Naoya Niimi and Takuya Tamatani and Masayuki Miyasaka and Yasunobu Yoshikai",
    year = "1995",
    month = "9",
    doi = "10.1006/cimm.1995.1173",
    language = "English",
    volume = "164",
    pages = "295--305",
    journal = "Cellular Immunology",
    issn = "0008-8749",
    publisher = "Academic Press Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis

    AU - Kobayashi, Yasushi

    AU - Kawai, Kuniyuki

    AU - Honda, Hitoshi

    AU - Tomida, Shin

    AU - Niimi, Naoya

    AU - Tamatani, Takuya

    AU - Miyasaka, Masayuki

    AU - Yoshikai, Yasunobu

    PY - 1995/9

    Y1 - 1995/9

    N2 - We obtained the evidence that coadministration in vivo of mAbs against leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) suppressed the progression of experimental allergic encephalomyelitis (EAE) in rats. The suppressive effect in vivo of coadministration of the mAbs during the induction phase was not prominent, but the administration of these mAbs during the effector phase markedly suppressed the progression of clinical illness and prevented the infiltration of encephalitogenic cells into the central nervous system. However, administration of the mAb to LFA-1 alone or ICAM-1 alone did not show such suppressive effects. These findings suggest that LFA-1 and ICAIM-1 are critically involved in the development of EAE and that the administration together of mAbs against adhesion molecules including LFA-1 and ICAM-1 might provide a new immunotherapeutic approach for the treatment of multiple sclerosis.

    AB - We obtained the evidence that coadministration in vivo of mAbs against leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) suppressed the progression of experimental allergic encephalomyelitis (EAE) in rats. The suppressive effect in vivo of coadministration of the mAbs during the induction phase was not prominent, but the administration of these mAbs during the effector phase markedly suppressed the progression of clinical illness and prevented the infiltration of encephalitogenic cells into the central nervous system. However, administration of the mAb to LFA-1 alone or ICAM-1 alone did not show such suppressive effects. These findings suggest that LFA-1 and ICAIM-1 are critically involved in the development of EAE and that the administration together of mAbs against adhesion molecules including LFA-1 and ICAM-1 might provide a new immunotherapeutic approach for the treatment of multiple sclerosis.

    UR - http://www.scopus.com/inward/record.url?scp=0029149732&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0029149732&partnerID=8YFLogxK

    U2 - 10.1006/cimm.1995.1173

    DO - 10.1006/cimm.1995.1173

    M3 - Article

    C2 - 7544693

    AN - SCOPUS:0029149732

    VL - 164

    SP - 295

    EP - 305

    JO - Cellular Immunology

    JF - Cellular Immunology

    SN - 0008-8749

    IS - 2

    ER -